Osteopontin splice variants differentially exert clini-copathological features and biological functions in gastric cancer

International Journal of Biological Sciences

Volumn 9, Issue 1, 2012, Pages 55-66

  Tang, Xiaojian ^a   Li, Jianfang ^a   Yu, Beiqin ^a   Su, Liping ^a   Yu, Yingyan ^a   Yan, Min ^a   Liu, Bingya ^a   Zhu, Zhenggang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis; Biological function; Clinicopathological feature; Gastric cancer; Metastasis; OPN splice variants

Indexed keywords

GELATINASE A; INTERLEUKIN 8; OSTEOPONTIN; UROKINASE;

APOPTOSIS; ARTICLE; BIOLOGICAL FUNCTION; CLINICOPATHOLOGICAL FEATURE; GENETICS; HUMAN; METABOLISM; METASTASIS.; OPN SPLICE VARIANTS; PATHOLOGY; PHYSIOLOGY; RNA SPLICING; STOMACH CANCER; STOMACH TUMOR; TUMOR CELL LINE;

APOPTOSIS; BIOLOGICAL FUNCTION; CLINICOPATHOLOGICAL FEATURE; GASTRIC CANCER; METASTASIS.; OPN SPLICE VARIANTS;

APOPTOSIS; CELL LINE, TUMOR; HUMANS; INTERLEUKIN-8; MATRIX METALLOPROTEINASE 2; OSTEOPONTIN; RNA SPLICING; STOMACH NEOPLASMS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84872195355     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.5280     Document Type: Article

References (37)

1. Cao DX, Li ZJ, Jiang XO, Lum YL, Khin E, Lee NP, et al. Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol. 2012; 18: 3923-30.
2. Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell. 1979; 16: 885-93.
3. Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med. 2010; 14: 2037-44.
4. Dai N, Bao Q, Lu A, Li J. Protein expression of osteopontin in tumor tissues is an independent prognostic indicator in gastric cancer. Oncology. 2007; 72: 89-96.
5. Lee JL, Wang MJ, Sudhir PR, Chen GD, Chi CW, Chen JY. Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res. 2007; 67: 2089-97.
6. Philip S, Kundu GC. Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem. 2003; 278: 14487-97.
7. Tuck AB, Hota C, Chambers AF. Osteopontin(OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Res Treat. 2001; 70: 197-204.
8. Hijiya N, Setoguchi M, Matsuura K, Higuchi Y, Akizuki S, Yamamoto S. Cloning and characterization of the human osteopontin gene and its promoter. Biochem J. 1994; 303 (Pt 1): 255-62.
9. Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Pre- and post-translational regulation of osteopontin in cancer. J Cell Commun Signal. 2011; 5: 111-22.
10. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, et al. Osteopontin-c is a selective marker of breast cancer. Int J Cancer. 2008; 122: 889-97.
11. Yan W, Qian C, Zhao P, Zhang J, Shi L, Qian J, et al. Expression pattern of osteopontin splice variants and its functions on cell apoptosis and invasion in glioma cells. Neuro Oncol. 2010; 12: 765-75.
12. Chae S, Jun HO, Lee EG, Yang SJ, Lee DC, Jung JK, et al. Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines. Int J Oncol. 2009; 35: 1409-16.
13. Tilli TM, Franco VF, Robbs BK, Wanderley JL, da Silva FR, de Mello KD, et al. Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol Cancer Res. 2011; 9: 280-93.
14. Sakakibara T, Hibi K, Koike M, Fujiwara M, Kodera Y, Ito K, et al. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of gastric cancer. Cancer Sci. 2006; 97: 395-9.
15. Wu F, Shirahata A, Sakuraba K, Kitamura Y, Goto T, Saito M, et al. Down-regulation of EGFL8: a novel biomarker for advanced gastric cancer. Anticancer Res. 2011; 31: 3377-80.
16. Junaid A, Moon MC, Harding GE, Zahradka P. Osteopontin localizes to the nucleus of 293 cells and associates with polo-like kinase-1. Am J Physiol Cell Physiol. 2007; 292: C919-26.
17. Feng R, Chen X, Yu Y, Su L, Yu B, Li J, et al. miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett. 2010; 298: 50-63.
18. Han H, Long H, Wang H, Wang J, Zhang Y, Wang Z. Progressive apoptotic cell death triggered by transient oxidative insult in H9c2 rat ventricular cells: a novel pattern of apoptosis and the mechanisms. Am J Physiol Heart Circ Physiol. 2004; 286: H2169-82.
19. Bordon E, Henriquez Hernandez LA, Lara PC, Pinar B, Fontes F, Rodriguez Gallego C, et al. Prediction of clinical toxicity in localized cervical carcinoma by radio-induced apoptosis study in peripheral blood lymphocytes (PBLs). Radiat Oncol. 2009; 4: 58.
20. Zhang Y, Pu X, Shi M, Chen L, Song Y, Qian L, et al. Critical role of c-Jun overexpression in liver metastasis of human breast cancer xenograft model. BMC Cancer. 2007; 7: 145.
21. Susnow N, Zeng L, Margineantu D, Hockenbery DM. Bcl-2 family proteins as regulators of oxidative stress. Semin Cancer Biol. 2009; 19: 42-9.
22. Deng X, Gao F, Flagg T, May WS, Jr. Mono- and multisite phosphorylation enhances Bcl2's antiapoptotic function and inhibition of cell cycle entry functions. Proc Natl Acad Sci U S A. 2004; 101: 153-8.
23. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell. 1996; 87: 619-28.
24. Noh S, Jung JJ, Jung M, Kim TS, Park CH, Lim SJ, et al. MMP-2 as a putative biomarker for carcinomatosis in gastric cancer. Hepatogastroenterology. 2011; 58: 2015-9.
25. Okusa Y, Ichikura T, Mochizuki H, Shinomiya N. Urokinase type plasminogen activator and its receptor regulate the invasive potential of gastric cancer cell lines. Int J Oncol. 2000; 17: 1001-5.
26. Strieter RM. Chemokines: not just leukocyte chemoattractants in the promotion of cancer. Nat Immunol. 2001; 2: 285-6.
27. Patani N, Jiang W, Mokbel K. Osteopontin C mRNA expression is associated with a poor clinical outcome in human breast cancer. Int J Cancer. 2008; 122: 2646.
28. Hahnel A, Wichmann H, Greither T, Kappler M, Wurl P, Kotzsch M, et al. Prognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients. BMC Cancer. 2012; 12: 131.
29. Chen W, Ma Q, Suzuki H, Hartman R, Tang J, Zhang JH. Osteopontin reduced hypoxia-ischemia neonatal brain injury by suppression of apoptosis in a rat pup model. Stroke. 2011; 42: 764-9.
30. Qiao L, Wong BC. Targeting apoptosis as an approach for gastrointestinal cancer therapy. Drug Resist Updat. 2009; 12: 55-64.
31. Jung T, Gross W, Zoller M. CD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance. J Biol Chem. 2011; 286: 15862-74.
32. Marhaba R, Bourouba M, Zoller M. CD44v7 interferes with activation-induced cell death by up-regulation of anti-apoptotic gene expression. J Leukoc Biol. 2003; 74: 135-48.
33. Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev. 2008; 27: 103-18.
34. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol. 2007; 14: 185-93.
35. Holland C, Schmid M, Zimny-Arndt U, Rohloff J, Stein R, Jungblut PR, et al. Quantitative phosphoproteomics reveals link between Helicobacter pylori infection and RNA splicing modulation in host cells. Proteomics. 2011; 11: 2798-811.
36. Collighan RJ, Griffin M. Transglutaminase 2 cross-linking of matrix proteins: biological significance and medical applications. Amino Acids. 2009; 36: 659-70.
37. He B, Mirza M, Weber GF. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene. 2006; 25: 2192-202.